IGF1 and schizophrenia: PUMICE+ identified novel drug classes, including VEGFR inhibitor for asthma, proteasome inhibitor for inflammatory bowel disease, Hsp90 inhibitor for rheumatoid arthritis, JAK inhibitor for vitiligo, SRC inhibitor for coronary artery disease, mTOR inhibitor for schizophrenia, and IGF-1 inhibitor for bipolar disorder, that may be worth investigating further.